Patents by Inventor Stephan Kontos
Stephan Kontos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11884721Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.Type: GrantFiled: January 7, 2021Date of Patent: January 30, 2024Assignee: École Polytechnique Fédérale de Lausanne (EPFL)Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
-
Publication number: 20230069712Abstract: Disclosed are compounds for the induction of antigen-specific immune tolerance in a subject, the compounds comprising an antigen, a polymeric linker and a liver targeting moiety, wherein the polymeric linker comprises a terminal end unit lacking each of a dithioester and a dithiobenzoate and wherein the terminal end unit confers improved stability to the compound when in solution.Type: ApplicationFiled: September 18, 2020Publication date: March 2, 2023Inventors: Stephan Kontos, Dilrukshi Vitharana, Sergey A. Isarov
-
Publication number: 20220211826Abstract: Several embodiments provided in the present disclosure relate to compositions that carry an antigen to which tolerance is desired, the antigen being coupled, bound, or otherwise joined to a targeting moiety, the targeting moiety configured to direct the composition to the liver of a subject. In several embodiments, the antigen in coupled to the targeting moiety by way of a polymeric linker. In several embodiments, the polymeric linker is configured to liberate the antigen in vivo. Methods of using the compositions to reduce and/or prevent unwanted immune responses against an antigen of interest are also provided.Type: ApplicationFiled: January 3, 2022Publication date: July 7, 2022Inventors: Jeffrey A. Hubbell, David Scott Wilson, Kristen Marie Lorentz, Stephan Kontos
-
Publication number: 20220153859Abstract: Several embodiments relate to antigen-binding proteins, such as antibodies, that hind to glycophorin A, In some embodiments, the antigen-binding proteins provided herein are fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind glycophorin A, Several embodiments relate to affinity-matured antigen-binding proteins. Several embodiments employ Next Generation Sequencing to predict, screen or otherwise characterize affinity matured candidates. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides.Type: ApplicationFiled: May 7, 2019Publication date: May 19, 2022Inventors: Stephan Kontos, Rose Jaskol Lewis, Julie Michelle Silverman, Jian Li, Gregory Paul Conley
-
Publication number: 20220125945Abstract: Erythrocyte-binding moieties coupled to tolerizing antigens are described. Provided for are peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The erythrocyte-binding moieties may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.Type: ApplicationFiled: January 4, 2022Publication date: April 28, 2022Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
-
Patent number: 11253579Abstract: Several embodiments provided in the present disclosure relate to compositions that carry an antigen to which tolerance is desired, the antigen being coupled, bound, or otherwise joined to a targeting moiety, the targeting moiety configured to direct the composition to the liver of a subject. In several embodiments, the antigen in coupled to the targeting moiety by way of a polymeric linker. In several embodiments, the polymeric linker is configured to liberate the antigen in vivo. Methods of using the compositions to reduce and/or prevent unwanted immune responses against an antigen of interest are also provided.Type: GrantFiled: June 14, 2018Date of Patent: February 22, 2022Assignees: The University of Chicago, Anokion SAInventors: Jeffrey A. Hubbell, David Scott Wilson, Kristen Marie Lorentz, Stephan Kontos
-
Patent number: 11246943Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.Type: GrantFiled: September 26, 2019Date of Patent: February 15, 2022Assignee: École Polytechnique Fédérale de Lausanne (EPFL)Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
-
Publication number: 20210238277Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.Type: ApplicationFiled: January 7, 2021Publication date: August 5, 2021Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
-
Publication number: 20210079077Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.Type: ApplicationFiled: September 3, 2020Publication date: March 18, 2021Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
-
Patent number: 10919963Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.Type: GrantFiled: July 26, 2019Date of Patent: February 16, 2021Assignee: École Polytechnique Fédérale de Lausanne (EPFL)Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
-
Patent number: 10800838Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.Type: GrantFiled: November 21, 2017Date of Patent: October 13, 2020Assignee: École Polytechnique Fédérale de Lausanne (EPFL)Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
-
Publication number: 20200101169Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.Type: ApplicationFiled: September 26, 2019Publication date: April 2, 2020Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
-
Publication number: 20200101146Abstract: Several embodiments provided in the present disclosure relate to compositions that carry an antigen to which tolerance is desired, the antigen being coupled, bound, or otherwise joined to a targeting moiety, the targeting moiety configured to direct the composition to the liver of a subject. In several embodiments, the antigen in coupled to the targeting moiety by way of a polymeric linker. In several embodiments, the polymeric linker is configured to liberate the antigen in vivo. Methods of using the compositions to reduce and/or prevent unwanted immune responses against an antigen of interest are also provided.Type: ApplicationFiled: June 14, 2018Publication date: April 2, 2020Inventors: Jeffrey A. Hubbell, David Scott Wilson, Kristen Marie Lorentz, Stephan Kontos
-
Publication number: 20190382479Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.Type: ApplicationFiled: July 26, 2019Publication date: December 19, 2019Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
-
Patent number: 10471155Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.Type: GrantFiled: February 23, 2018Date of Patent: November 12, 2019Assignee: École Polytechnique Fédérale de Lausanne (EPFL)Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
-
Patent number: 10392437Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.Type: GrantFiled: November 21, 2016Date of Patent: August 27, 2019Assignee: École Polytechnique Fédérale de Lausanne (EPFL)Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
-
Patent number: 10265415Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.Type: GrantFiled: February 23, 2018Date of Patent: April 23, 2019Assignee: École Polytechnique Fédérale de Lausanne (EPFL)Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
-
Patent number: 10265416Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.Type: GrantFiled: February 23, 2018Date of Patent: April 23, 2019Assignee: École Polytechnique Fédérale de Lausanna (EPFL)Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
-
Publication number: 20180185507Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.Type: ApplicationFiled: February 23, 2018Publication date: July 5, 2018Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
-
Publication number: 20180185508Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.Type: ApplicationFiled: February 23, 2018Publication date: July 5, 2018Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane